CClinicalTrials.gg
RecruitingNCT05778903Updated Apr 3, 2024

Maxillary Nerve Blocks in Children - An MRI Study of the Suprazygomatic Approach

An interventional study of Nerve block in Nerve Block, Cleft Palate and Analgesia, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 10 Months to 24 Months. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
10 Months to 24 Months
Sex
All
01

Study summary

Ultrasound-guided suprazygomatic maxillary nerve block (SMNB) will be performed in paediatric patients with or without the aid of ultrasound guidance. Magnetic resonance imaging (MRI) is used to visualize the spread of the local anaesthetic (LA) spread after suprazygomatic injection and to verify LA contact with the maxillary nerve in the pterygopalatine fossa (PPF).

02

Conditions studied

  • Nerve Block
  • Cleft Palate
  • Analgesia

Browse trials for

03

In context

Cleft Palate

131 studies on the registry are indexed under Cleft Palate; 36 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 85 interventional studies indexed under Cleft Palate.

Browse Cleft Palate studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Paediatric patients scheduled for cleft palate (CP) surgery with SMNB as part of their perioperative pain treatment
  • American Society of Anesthesiologists physical status 1 - 2
  • Age 10 to 24 months
  • Given informed written consent by legal guardian

Exclusion criteria

Exclusion Criteria:

  • American Society of Anesthesiologists physical status > 2
  • Patients with cranial deformation
  • Patients with concomitant medical treatments or medical conditions interfering with peripheral nerve block treatment
  • Patients with concomitant medical treatments or medical conditions interfering with MRI
  • Patients that are allergic to bupivacaine or other local anaesthetic agents.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Ultrasound guided Suprazygomatic Maxillary Nerve Block

    An ultasound guided SMNB is admitted on one half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.

    Other: Nerve block

  • Active comparator
    Landmark guided Suprazygomatic Maxillary Nerve Block landmark

    A langmark guided SMNB is admitted on the other half of the patients face (left or right) according to randomiced allocation. 0.15 ml/kg of bupivacaine 0.25 mg/ml with epinephrin 5 mcg/ml is injected.

    Other: Nerve block

Interventions

  • OtherNerve block

    Suprazygomatic maxillary nerve block

06

What researchers measure

Primary outcomes

  1. Rate of LA spread into the PPF

    Local anesthetic spread to the maxillaris nerve in the pterygopalatine fossa detected by MRI (binary outcome)

    Time frame: day one - within an hour after intervention (peripheral nerve block)

Secondary outcomes

  1. Rate of LA spread to other anatomical areas and structures

    Local anaesthetic spread to orbita, nasal cavity, cranial fossa, infratemporal fossa, or other structures detected by MRI (binary outcome)

    Time frame: day one - within an hour after intervention (peripheral nerve block)

  2. Rate of hematoma

    Accumulation of blood detected by MRI (binary outcome)

    Time frame: day one - within an hour after intervention (peripheral nerve block)

  3. Superior-inferior needle angle

    Angle of the injection needle meassured in a coronal plane

    Time frame: day one - immediately after intervention (peripheral nerve block)

  4. Anterior-posterior needle angle

    Angle of the injection needle meassured in a sagittal plane

    Time frame: day one - immediately after intervention (peripheral nerve block)

  5. Needle depth

    Depth of the injection needle

    Time frame: day one - immediately after intervention (peripheral nerve block)

  6. Side effects and adverse events

    All side effects or adverse events that might be detected

    Time frame: day one

  7. Postoperative analgesic consumption

    Opioid consumption during the first 24 hours after surgery

    Time frame: day one and day two

  8. MRI time

    Time consumption for MRI

    Time frame: day one

07

Study locations

1 of 1 sites recruiting
  • Oslo University Hospital
    Oslo, 0488, Norway
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05778903
Lead sponsor
Oslo University Hospital
Responsible party
Axel R. Sauter (Principal Investigator, Oslo University Hospital) — Principal investigator
First posted
Mar 21, 2023
Start date
Jun 7, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 3, 2024

Study contacts

Axel Sauter, MD PhD
Contact
axsa@online.no
93484022 ext. +47
Nergis Suleiman, MD
Contact
nergis.nina.suleiman@gmail.com
23070000 ext. +47
Axel Sauter, MD PhD
principal investigator · Oslo University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion